glp 1 and eating disorders GLP-1 RAs in Disorders: Promising or Perilous? Use and misuse of GLP-1

B.DingW

On rest days, take it in the morning to support fat metabolism

Additional SURMOUNT Trials Cardiovascular Outcomes Trials SURPASS-CVOT (NCT04255433) Study Title: "Cardiovascular Outcomes Following Tirzepatide Treatment in Participants With Type 2 Diabetes and Increased Cardiovascular Risk" Status: Ongoing Phase: Phase 3 Enrollment: ~12,500 participants Study Period: 2020-2025 (estimated) Design: Randomized, double-blind, placebo-controlled event-driven trial Duration: Event-driven (minimum 3 years) Intervention: Tirzepatide up to 15 mg vs

Its the most abundant amino acid in the body and becomes especially important during times of physical stress, intense training, or illness

There is an urgent need for a pharmacological agent that can specifically and safely correct the shared metabolic pathology, ideally by acting at both central (e.g., controlling appetite and cravings) and peripheral (e.g., improving insulin sensitivity, reducing hepatic fat and inflammation) levels to support and enhance existing behavioral strategies, thereby lowering the risk of advanced liver disease development across metabolic and alcoholic etiologies

E.vanden HovenR